AstraZeneca has announced that it has received marketing authorization from the European Commission for its Fluenz nasal spray vaccine for the prevention of seasonal flu in children under 18 years old down to 24 months old. Fluenz is marketed in the US as FluMist by MedImmune. Read the company’s press release.
EC approves Fluenz intranasal flu vaccine for use in children
published on
Featured event:
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
